This hospital-based prospective study of severe HFMD patients is needed and could provide important evidence on severe HFMD. I am concerned that the comprehensive neurological assessment is conducted every 2 years during the follow-up, I think the interval between consecutive follow-ups is a little long in the early stage, because past studies indicate that substantial changes can occur during the first two years.
1. The first objective of this study is to develop early warning tools for CNS involvement using early biomarkers and clinical manifestations, however, I did not find clear restrictions on the time of enrolment, e.g., within X days of illness onset or within X days of admission. Also, for the studies on prognostic indicators, the endpoint needs to be determined, but there are no related descriptions in the current protocol.
2. According to the protocol, one strength of the study is that this cohort is "larger" compared with past studies, but the sample size is not specified. I think there could be different sample size requirements for the prognostic study (early warning) and the followup study (sequela), respectively. 2a. Please specify the sample size in the Abstract and the main text. 2b. Please provide a sample size justification / power analysis.
3. The third objective is to build an HFMD biobank for future research activities, the volume of the biological samples (such as blood) should be specified.
4. In terms of the eligibility of enrolled participants, in "Baseline clinical and laboratory data" of "Data collection", it is described that "All the study participants are laboratory-confirmed for HFMD using throat/anal swab polymerase chain reaction (PCR) technique", I am a little confused that whether only lab-confirmed cases are included or not. Also, in the exclusion criteria, cases complicated with other infectious diseases at admission will be excluded, it could rule out the effects of other infectious diseases, but how this is achieved require more details or the scope of "other infectious diseases" had be defined. For instance, how could the researcher judge whether a HFMD case is complicated with another viral infection or not?
5. Abstract -limitations -would selection bias also be an issue, given enrolment is from a large tertiary referral paediatric hospital? This hospital might receive some of the most severe and complicated cases, compared to "average" severe HFMD?
6. Methods -follow-up -does biannual mean twice per year or once every two years? Perhaps change to "every 6 months" if that is the idea.
7. I do not understand why the paragraph of analysis of retrospective data (2011) (2012) (2013) (2014) (2015) (2016) (2017) is put in the article, with Figure 2 . It seems that this paragraph and the following one "Some relevant studies…" are not relevant to this cohort profile? This hospital-based prospective study of severe HFMD patients is needed and could provide important evidence on severe HFMD. I am concerned that the comprehensive neurological assessment is conducted every 2 years during the follow-up, I think the interval between consecutive follow-ups is a little long in the early stage, because past studies indicate that substantial changes can occur during the first two years.
REVIEWER
In the previous studies, there was only one single follow-up neurological assessment that was conducted 3 years (in average) after discharge, while the earliest assessment was given about 1 year after discharge (PMIDs:17377160, 17116698, 24534397) . Therefore, we decide to perform our first and second post-hospital assessments at 1 and 2 years after discharge, respectively. The advantage of doing so is that we will be able to detect the occurrence of short-term neurological deficits. Accordingly, we have described this change in the revision (page 2 line 15-16 and page 9 line 7-8).
We thank the reviewer for raising the question about the missing restriction on the time of enrolment since disease onset or admission. However, we have decided not to use such a restriction because it will: 1) cause severe selection bias; 2) reduce the size of the cohort; and 3) do not allow the use of the time from disease onset to admission/diagnosis as a risk factor to predict CNS complications. We have clarified this issue in the revision (Page 13 line 20-22).
CNS involvement is one of the major outcomes of this study. There was a definition of CNS involvement (severe HFMD) in the initial submission (page 6 line 10-14). In order to emphasize this definition, we have made it stand out as an independent paragraph with a sub-heading named Definition of CNS and severe HFMD (page 8 line 8-14) in the Data collection section.
2. According to the protocol, one strength of the study is that this cohort is "larger" compared with past studies, but the sample size is not specified. I think there could be different sample size requirements for the prognostic study (early warning) and the followup study (sequela), respectively.
Data of the past 5 years show that we had about 1,200 hospitalized HFMD each year and the incidence of CNS involvement was about 10%; therefore, we expect that during the recruitment period (2018-2023), our cohort will include more than 4,000 patients after exclusion, among them 400 patients might develop CNS complications. As suggested by the reviewer, we performed a power analysis showing that a cohort of n=4,000 participants has a statistical power of 80% to detect a moderate but "true" relative risk of 1.5 for a relatively rare risk factor (prevalence = 10%), given a type II error of 0.05, an overall incidence rate of 10% for the studied event (CNS involvement in our case), and a rate of 10% for loss to follow-up. We have added a paragraph in the revision to justify the adequacy of our sample size (page 7 line 3-10).
We did not consider sample size calculation for the follow-up study because we did not make any statistical hypothesis concerning the incidence rate of neurological sequelae which we aim to acquire (i.e. a null hypothesis that the incidence is equal to a specific figure).
2a. Please specify the sample size in the Abstract and the main text.
We have added in the revision a sample size description in the Abstract (page 2 line 10) and the main text (page 7 line 3-10).
2b. Please provide a sample size justification / power analysis.
Please refer to above our response to the power analysis issue.
3.
The third objective is to build an HFMD biobank for future research activities, the volume of the biological samples (such as blood) should be specified.
We have provided more information in the revision about the volumes of the biological samples and how they are stored (page 7 line 18-20 and page 7 line 22 -page 8 line 1).
4.
In terms of the eligibility of enrolled participants, in "Baseline clinical and laboratory data" of "Data collection", it is described that "All the study participants are laboratoryconfirmed for HFMD using throat/anal swab polymerase chain reaction (PCR) technique", I am a little confused that whether only lab-confirmed cases are included or not. Also, in the exclusion criteria, cases complicated with other infectious diseases at admission will be excluded, it could rule out the effects of other infectious diseases, but how this is achieved require more details or the scope of "other infectious diseases" had be defined. For instance, how could the researcher judge whether an HFMD case is complicated with another viral infection or not?
We should make it clear that lab-confirmation via PCR is not a part of the inclusion criteria of recruitment but rather a test for a virological diagnosis we would like to make during the study and to use as predictor for subsequent CNS involvement. In the revision, we have rephrased the sentence and now it reads "For patients who have been enrolled in the cohort, a virological diagnosis will be made using throat/anal swab polymerase chain reaction (PCR) technique." (page 7 line 17-18).
With respect to the third exclusion criterion, namely, excluding patients "complicated with other infectious diseases at admission", we think the initial expression is too general and inexplicit; therefore the reviewer's comment is very relevant. In the revision (page 6 line 16-18), we have specified that these "other infectious diseases" are those that might have also lead to CNS and pulmonary complications and they should be excluded to avoid the otherwise confounded prognoses. Pathogens under our consideration include herpes simplex virus, cytomegalovirus, Epstein-Barr virus, varicella zoster virus, respiratory syncytial virus, adenovirus, chlamydia pneumoniae, mycoplasma pneumoniae, and pneumococcus. All these infections will be confirmed by serological tests. A corresponding change has also been made in Figure 1 (see "Exclusion criteria").
5.
Abstract -limitations -would selection bias also be an issue, given enrolment is from a large tertiary referral paediatric hospital? This hospital might receive some of the most severe and complicated cases, compared to "average" severe HFMD?
We agree with the reviewer that selection bias is a major issue, and our study is subject to this bias at both recruitment and follow-up stages, which is important but we failed to discuss in the initial submission. In the revision we have added a brief discussion about the selection bias and its possible causes (page 13 line 13-22). The idea of providing retrospective data was that we would like to inform readers of the burden of HFMD in our hospital, which we think is relevant to the estimation of the size our cohort), so we would like to keep Figure 2 but as an appendix form (the Appendix Figure in the revision). We have deleted Table 1 and the paragraph describing previous publications from our institute, which we agree are irrelevant (page 10 line 16 -page 11 line 11). Which therapeutic consequences will arise from the findings of risk factors and biomarkers?
We hope that we are able to develop a clinical tool out of the results of this study, and we hope that this tool is informative enough so that it can guide physicians to admit high-risk patients into hospital for close observation without delay and can gain time for further investigations, which will lead to early initiation of supportive and symptomatic treatment.
2.
HFMD is an exanthema that often affects adults. Should these be included in the study?
We are not going to include adult HFMD patients in our cohort. We do occasionally encounter adult HFMD patients, but these patients usually are very few and they only need outpatient care.
